Navigation Links
UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
Date:9/4/2007

Charlottesville, Va., September 4, 2007 A University of Virginia researcher has been awarded a $3.6 million grant from the National Institute of Allergy and Infectious Diseases to combat a growing international health crisis.

Dr. Richard Guerrant, founder of UVas Center for Global Health, plans to take a unique approach to treating the bacterium Clostridium difficile, which is growing increasingly resistant to certain antibiotics that work against bacteria of the colon. Clostridium difficile (C. diff) is a bacterium that causes diarrhea and can lead to more serious intestinal conditions such as colitis.

This is a huge problem which has been getting worse since the mid-1980s. Previously healthy young people are becoming ill with the disease and the national mortality rate from the disease has more than doubled in the last few years, Guerrant says.

Patients who are most at risk from C. diff have traditionally been older or have taken antibiotics for an extended period of time. The antibiotics eradicate the beneficial bacteria which all people have in their digestive tract, leaving the drug resistant C. diff to flourish. An estimated 5 to 7 percent of residents of assisted living and nursing facilities are infected with the bacterium.

The Centers for Disease Control reports there have been C. diff outbreaks in hospitals in 23 states. The drug-resistant strain has been blamed for more than 100 deaths over an 18-month period at a hospital in Quebec. The bacteria are found in feces. Infection can occur when people touch items or surfaces contaminated with feces.

C. difficile produces two toxins which cause the body to react with diarrhea, fever, loss of appetite, nausea and abdominal pain. Because the bacterium is proving resistant to antibiotics, Guerrant proposes countering the effects of the toxins instead of targeting the bacterium.

The current treatments have been to try a new antibiotic on the bacterium, which kills even more of the beneficial bacteria and allows C. diff to continue ravaging the patients, Guerrant says. By rendering the toxins harmless, we hope we can keep the debilitating effects of C. diff from proving fatal.

Guerrant says pilot data show this approach has great promise and he plans to collaborate with other UVa scientists and a pharmaceutical company to develop the treatment.


'/>"/>

Contact: David Foreman
davidforeman@virginia.edu
434-924-2242
University of Virginia Health System
Source:Eurekalert

Related medicine news :

1. Researchers urge caution in using ear tube surgery
2. Researchers Scale to assess the Severity of Epilepsy in Kids
3. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
4. New Hair in 15 Days Could Now Be A Possibility Say Researchers
5. Researchers at Cornell University as been reported using research fund by false claims
6. Researchers trick Alzheimers Enzyme
7. Researchers find new HIV hiding place
8. Gene researchers make Malaria-resistant mosquito
9. Researchers developed world’s smallest toothbrus
10. Researchers discover receptor cells that can cause epilepsy
11. 15 Anti-SARS Drugs Identified By China-Europe Team of Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology: